Encorafenib vs HLX208

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: BRAF V600E · full Non-Small Cell Lung Cancer pipeline

Encorafenib

Marketed by Pfizer and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT03915951 · Phase 2 · completed

The study was open-label, single-group, and had no placebo or active comparator, so the objective response results cannot be directly attributed to the treatment relative to another therapy. Its primary radiographic response endpoint was reported separately for 59 treatment-naive and 39 previously treated participants, but there was no formal between-group primary comparison.

Reported efficacy

Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8) (not_applicable)

Result source: NCT03915951

HLX208

Developed by Shanghai Henlius Biotech and partners

Phase 2 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05065398 · Phase 2 · status unknown

This is a small, open-label, single-arm study with no control group, so there is no formal comparison to test HLX208's benefit against, and it enrolls only about 20 patients. No results have been posted yet.

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEncorafenibHLX208
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR74.6%bn 59NCT03915951
3 other results
—Not reported
Duration of response, median—Not reported—Not reported

PFS, median

Encorafenib
—Not reported
HLX208
—Not reported

OS, median

Encorafenib
—Not reported
HLX208
—Not reported

ORR

Encorafenib
74.6%bn 59NCT03915951
3 other results
HLX208
—Not reported

Duration of response, median

Encorafenib
—Not reported
HLX208
—Not reported
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HLX208: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Encorafenib: 3 of 4 rows · HLX208: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEncorafenib
Dropout rate
n/a: no completion milestonePreviously Treateda
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 2 more results
n/a: no completion milestoneTreatment-Naive
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
n/a: no completion milestone
NCT05003622 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
15.4%Previously Treateda
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 2 more results
20.3%Treatment-Naive
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
—
NCT05003622 · Phase 1 · registry result, not featured evidence
Serious AEs
43.6%Previously Treateda
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 2 more results
42.4%Treatment-Naive
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
66.7%
NCT05003622 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
diarrhoea 51.3%
nausea 48.7%
fatigue 41%
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 2 more results
nausea 62.7%
diarrhoea 49.2%
fatigue 49.2%
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
neutrophil count increased 100%
proteinuria 100%
constipation 66.7%
NCT05003622 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Encorafenib

ORR 74.6% (n=59)
responder rate · % of participants
No placebo or comparator arm
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 3 more results
46.2% (n=39)
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
62.7% (n=59)
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
41% (n=39)
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
Disease Control 64.4% (n=59) @ 24wk
responder rate · % of participants
No placebo or comparator arm
DCR After 24 Weeks by IRR
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 1 more result
41% (n=39) @ 24wk
DCR After 24 Weeks by IRR
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
Time to Response 1.86 months
time to event · months
No placebo or comparator arm
TTR by IRR
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 1 more result
1.74 months
TTR by IRR
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Encorafenib's landscape · HLX208's landscape